Risk factors for hepatitis B in an outbreak of hepatitis B and D among injection drug users

Journal of Urban Health

Volumn 82, Issue 3, 2005, Pages 468-478

  Bialek, Stephanie R ^a   Bower, William A ^a   Mottram, Karen ^b   Purchase, Dave ^c   Nakano, T ^a   Nainan, Omana ^a   Williams, Ian T ^a   Bell, Beth P ^a  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b Tacoma Pierce Co Health Department   (United States)

^c Point Defiance AIDS Projects   (United States)

Author keywords

Hepatitis B; Hepatitis D; Intravenous drug abuse

Indexed keywords

DIAMORPHINE;

ACUTE HEPATITIS; ADULT; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DELTA AGENT HEPATITIS; DRUG ABUSE; EPIDEMIC; FEMALE; HEALTH SURVEY; HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS DELTA VIRUS; HEROIN DEPENDENCE; HUMAN; INFECTION CONTROL; INFECTION RISK; INJECTION; MALE; MORTALITY; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; RISK; RISK FACTOR; SEXUAL BEHAVIOR; SUBSTANCE ABUSE; SYRINGE; UNITED STATES; VACCINATION; VIRUS TRANSMISSION;

ACUTE DISEASE; ADOLESCENT; ADULT; CASE-CONTROL STUDIES; DISEASE OUTBREAKS; FEMALE; HEPATITIS B; HEPATITIS D; HUMANS; IMMUNIZATION PROGRAMS; MALE; MIDDLE AGED; NEEDLE-EXCHANGE PROGRAMS; RISK FACTORS; SEXUAL BEHAVIOR; SUBSTANCE ABUSE, INTRAVENOUS; URBAN HEALTH;

EID: 23944495836     PISSN: 10993460     EISSN: None     Source Type: Journal    
DOI: 10.1093/jurban/jti094     Document Type: Article

References (35)

1. Centers for Disease Control and Prevention. Hepatitis Surveillance Report 57. Atlanta, GA: CDC; 2000.
2. Garfein RS, Vlahov D, Galai N, et al. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health. 1996;86:655-661.
3. Murrill CS, Weeks H, Castrucci BC, et al. Age-specific seroprevalence of HIV, hepatitis B virus, and hepatitis C virus infection among injection drug users admitted to drug treatment in 6 US cities. Am J Public Health. 2002;92:385-387.
4. Dhopesh VP, Taylor KR, Burke WM. Survey of hepatitis B and C in addiction treatment unit. Am J Drug Alcohol Abuse. 2000;26:703-707.
5. Lopez-Zetina J, Kerndt P, Ford W, et al. Prevalence of HIV and hepatitis B and self-reported injection risk behavior during detention among street-recruited injection drug users in Los Angeles County, 1994-1996. Addiction. 2001;96:589-595.
6. Polish LB, Gallagher M, Fields HA, et al. Delta hepatitis: molecular biology and clinical and epidemiological features. Clin Microbiol Rev. 1993;6:211-229.
7. DesJarlais C, Perlis T, Friedman SR, et al. Behavioral risk reduction in a declining HIV epidemic: injection drug users in New York City, 1990-1997. Am J Public Health. 2000;90:1112-1116.
8. Crofts N, Aitken CK. Incidence of bloodborne virus infection and risk behaviours in a cohort of injecting drug users in Victoria, 1990-1995. Med J Aust. 1997;167:17-20.
9. Cook PA, McVeigh J, Syed Q, et al. Predictors of hepatitis B and C infection in injecting drug users both in and out of drug treatment. Addiction. 2001;96:1787-1797.
10. McCoy CB, Metsch LR, Chitwood DD, et al. Parenteral transmission of HIV among injection drug users: assessing the frequency of multiperson use of needles, syringes, cookers, cotton, and water. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:S25-S29.
11. Thiede H, Romero M, Bordelon K, et al. Using a jail-based survey to monitor HIV and risk behaviors among Seattle area injection drug users. J Urban Health. 2001;78:264-278.
12. Hunter GM, Donoghoe MC, Stimson GV, et al. Changes in the injecting risk behaviour of injecting drug users in London, 1990-1993. AIDS. 1995;9:493-501.
13. Hagan H, Thiede H. Changes in injection risk behavior associated with participation in the Seattle needle-exchange program. J Urban Health. 2000;77:369-382.
14. Koester S, Hoffer L. "Indirect sharing": additional HIV risks associated with drug injection. AIDS Public Policy J. 1994;3:100-105.
15. Mansson AS, Moestrup T, Nordenfelt E, et al. Continued transmission of hepatitis B and C viruses, but no transmission of human immunodeficiency virus among intravenous drug users participating in a syringe/needle exchange program. Scand J Infect Dis. 2000;32:253-258.
16. Thorpe LE, Ouellet LJ, Hershow R, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol. 2002;155:645-653.
17. Centers for Disease Control and Prevention. Hepatitis B vaccination for injection drug users - Pierce County, Washington, 2000. MMWR Morb Mortal Wkly Rep. 2001;50:388-390, 399.
18. Nakano T, Shapiro CN, Hadler SC, et al. Characterization of hepatitis D virus genotype III among Yucpa Indians in Venezuela. J Gen Virol. 2001;82:2183-2189.
19. Nainan OV, Cromeans TL, Margolis HS. Sequence-specific, single-primer amplification and detection of PCR products for identification of hepatitis viruses. J Virol Methods. 1996;61:127-134.
20. Nainan OV, Stevens PE, Taylor PE, et al. Hepatitis B virus (HBV) antibody resistant mutants among mothers and infants with chronic HBV infection. In: Rizetto, M, Purcell, RH, Gerin, JL, Verme, G, eds. Viral Hepatitis and Liver Disease. Turin, Italy: Edizioni Minerva Medica; 1997:132-134.
21. Devereux J, Haeberli P, Smithies O. A comprehensive set of sequence analysis programs tor the VAX. Nucleic Acids Res. 1984;12:387-395.
22. Abdala N, Reyes R, Carney JM, et al. Survival of HIV-1 in syringes: effects of temperature during storage. Subst Use Misuse. 2000;35:1369-1383.
23. Clatts MC, Heimer R, Abdala N, et al. HIV-1 transmission in injection paraphernalia: heating drug solutions may inactivate HIV-1. J Acquir Immune Defic Syndr. 1999;22:194-199.
24. Shah SM, Shapshak P, Rivers JE, et al. Detection of HIV-1 DNA in needle/syringes, paraphernalia, and washes from shooting galleries in Miami: a preliminary laboratory report. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;11:301-306.
25. Heimer R, Khoshnood K, Jariwala-Freeman B, et al. Hepatitis in used syringes: the limits of sensitivity of techniques to detect hepatitis B virus (HBV) DNA, hepatitis C virus (HCV) RNA, and antibodies to HBV core and HCV antigens. J Infect Dis. 1996;173:997-1000.
26. Bond WW, Favero MS, Petersen NJ, et al. Survival of hepatitis B virus after drying and storage for one week. Lancet. 1981;1:550-551.
27. van Bueren J, Simpson RA, Jacobs P, et al. Survival of human immunodeficiency virus in suspension and dried onto surfaces. J Clin Microbiol. 1994;32:571-574.
28. Alter MJ, Hadler SC. Delta hepatitis and infection in North America. Prog Clin Biol Res. 1993;382:243-250.
29. Vlahov D, Junge B, Brookmeyer R, et al. Reductions in high-risk drug use behaviors among participants in the Baltimore needle exchange program. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:400-406.
30. Hagan H, DesJarlais DC, Purchase D, et al. An interview study of participants in the Tacoma, Washington, syringe exchange. Addiction. 1993;88:1691-1697.
31. Hagan H, Jarlais DC, Friedman SR, et al. Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program. Am J Public Health. 1995;85:1531-1537.
32. Hagan H, McGough JP, Thiede H, et al. Syringe exchange and risk of infection with hepatitis B and C viruses. Am J Epidemiol. 1999;149:203-213.
33. Hutchinson SJ, Goldberg DJ, Gore SM, et al. Hepatitis B outbreak at Glenochil prison during January to June 1993. Epidemiol Infect. 1998;121:185-191.
34. Stevenson J, Tannahill M, Biggs V. An outbreak of acute hepatitis B infection among injecting drug users in Inverclyde, Scotland. Commun Dis Public Health. 2001;4:60-63.
35. Streetly A, Perkins A, Tucker KM, et al. An outbreak of hepatitis B among intravenous drug users in Medway. Community Med. 1988;10:147-155.